PONYNOV

What PONYNOV does

PolyNovo Limited is an Australian-listed medical device company (ASX: PNV) that develops and commercializes products based on its proprietary NovoSorb bioabsorbable polyurethane polymer platform. The company's core commercial product is NovoSorb BTM (Biodegradable Temporizing Matrix), a synthetic bilayer dermal substitute consisting of a temporary non-biodegradable sealing membrane and a 2mm bioabsorbable open-cell matrix that facilitates dermis regeneration and is fully absorbed in approximately 18 months. A second product, NovoSorb MTX, is a flexible monolayer dermal matrix for soft-tissue reconstruction. Both products target complex wound management, burn care, and surgical reconstruction, serving plastic surgeons, reconstructive surgeons, burn specialists, vascular surgeons, podiatric surgeons, and wound care specialists across hospitals and healthcare facilities.

The company generates revenue primarily through direct sales of its medical devices to healthcare facilities and via third-party distributors globally, with market access in 37 countries as of 2023. The company maintains wholly-owned subsidiaries in the UK, EU, Switzerland, USA, and Singapore, and operates a manufacturing facility in Port Melbourne, Australia, with a regional headquarters in Carlsbad, California. The business model is enterprise field sales targeting healthcare professionals, supported by an evidence-based go-to-market strategy including webinars, case studies, peer-reviewed publications, and clinical education programs.

PolyNovo's regulatory moat is anchored by FDA 510(K) clearance (2015), Australian TGA registration (2018), European CE Mark (2019), and FDA Breakthrough Device Designation (2019). The company has received $36 million in non-dilutive funding from BARDA to support a pivotal trial for full-thickness burns, with the first patient enrolled in 2021. The technology platform is differentiated by its synthetic composition, which is not a food source for bacteria, requires no cold-chain storage, and is typically less expensive than biologic alternatives, with clinical evidence showing 94% average BTM take and 98% skin graft take rates across 241 patients in published literature.

Name

PONYNOV

Legal name

PolyNovo Limited

Website

https://polynovo.com

Company type

Public

Founded year

2004

Operating status

Operating

Headcount range

101–250 employees

Short description

PolyNovo Limited (ASX: PNV) is an Australian medical device company that develops and commercializes NovoSorb polymer-based dermal matrices (BTM and MTX) for wound management, burn care, and surgical reconstruction, selling directly and via distributors to hospitals and healthcare facilities across 37 countries.

Ownership category

akta.pro rank

Product category

Medical Devices - Wound Care & Dermal Reconstruction

NAICS

Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113), Medical Equipment and Supplies Manufacturing (3391)

SIC

Surgical & Medical Instruments & Apparatus (3841), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)

akta.pro primary industry

Biodegradable Polymers & Resins (PLA, PHA, PBS, PBAT) (IMAEAOAA)

Keywords

• Biodegradable medical devices
• Wound care solutions
• Dermal substitutes
• Burn treatment products
• Synthetic polymer implants

Headquarters

HQ city

Port Melbourne

HQ country

Australia

HQ region

Oceania

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Medical Device Sales: PolyNovo generates revenue through the sale of its NovoSorb medical devices (BTM and MTX) to healthcare facilities including hospitals, clinics, and surgical centers. Products are sold directly through the company's sales organization and via third-party distributors globally.
2. Global Distribution: Products are marketed and sold globally via PolyNovo's subsidiaries and third-party distributors around the world, creating multiple revenue channels across different geographic markets.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels6 records

Core offering

PolyNovo develops, manufactures, and commercializes NovoSorb BTM (Biodegradable Temporizing Matrix) and NovoSorb MTX, synthetic bioabsorbable polymer dermal matrix devices used by surgeons and wound care specialists for complex wound reconstruction, burn treatment, and surgical soft-tissue repair. The products are sold globally to hospitals, burn centers, trauma centers, and wound care clinics through direct sales subsidiaries and third-party distributors across 37 countries.

Product overview

PolyNovo is a medical device company that develops and commercializes innovative products based on its proprietary NovoSorb technology platform. The product portfolio consists of two main synthetic dermal matrix products: NovoSorb BTM (Biodegradable Temporizing Matrix), a bilayer matrix with a temporary sealing membrane and bioabsorbable scaffold, and NovoSorb MTX, a monolayer scaffold variant. Both products are designed for wound healing and soft tissue reconstruction, with BTM being the first commercially available NovoSorb product launched in 2015 following FDA 510(K) clearance. The products leverage the same underlying NovoSorb bioabsorbable polymer technology but serve different clinical needs based on wound type and treatment approach.

Differentiator

Problem solved

Functional benefit

Brands

• NovoSorb BTM: Biodegradable Temporizing Matrix - a synthetic, biodegradable and biocompatible bilayer dermal substitute for wound management
• NovoSorb MTX
• NovoSorb Technology

Quantifiable outcome

• Average 94% NovoSorb BTM take rate across 241 patients in published clinical literature
• +5 more outcomes

Named customers7 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Two partnerships are on record, tiered regulatory and foundational.

• US FDAregulatoryOthers · 1 January 2021In 2021, the first patient was enrolled in the BARDA and US FDA pivotal trial for NovoSorb BTM. The FDA granted Breakthrough Device Designation in 2019 and continues to work with PolyNovo on the regulatory pathway.
• CSIRO (Commonwealth Scientific and Industrial Research Organisation)foundationalStrategic or Co-development Partner · 1 January 2004Collaboration began in 2004 between CSIRO and PolyNovo with Professor John Greenwood, resulting in the development of NovoSorb BTM technology. This foundational partnership created the patented bioabsorbable polymer technology that underlies PolyNovo's product portfolio.

Scale indicators4 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• ConvaTec: ConvaTec is a global wound care and ostomy company with advanced wound care products targeting chronic wounds. It serves the same hospital and wound care clinic customers as PolyNova, though it is not a direct competitor in synthetic dermal regeneration matrices.
• Smith+Nephew: Smith+Nephew is a global wound care leader with extensive skin substitute and advanced wound management portfolios. While not directly competing in the dermal regeneration matrix niche, it is a broad incumbent shaping the wound care market in which PolyNova operates.
• Mölnlycke Health Care: Mölnlycke is a major wound care and surgical solutions company with Mepitel and other advanced wound care products. It competes in the broader burn and wound care space where PolyNova's BTM is positioned, though Mölnlycke is not focused on synthetic dermal regeneration matrices.
• 3M Health Care (KCI / Solventum): 3M's health care business (now Solventum) includes KCI's V.A.C. negative pressure wound therapy and other advanced wound care products. It addresses the same complex wound care use cases as PolyNova BTM, though through different mechanisms and as part of a much broader portfolio.
• Coloplast: Coloplast is a major wound care and skin care company with the Biatain portfolio. It competes in the broader wound care market served by PolyNova's products, particularly in chronic wound management, but is not a direct competitor in the dermal regeneration template niche.

Direct peers

• Organogenesis: Organogenesis manufactures Apligraf, a biologic skin substitute, and competes in wound care and surgical recovery. Apligraf represents one of the biologic alternatives that PolyNova's synthetic BTM is positioned against for complex wound and burn applications.
• Integra LifeSciences: Integra LifeSciences is the incumbent leader in dermal regeneration templates with Integra DRT, the dominant alternative to NovoSorb BTM. Head-to-head clinical comparisons (e.g., MetroHealth 51-patient series) directly benchmark PolyNova's BTM against this product, making it the most direct competitor in the synthetic dermal matrix space.
• MiMedx: MiMedx markets dehydrated amniotic membrane allografts (EpiFix, AmnioFix) for wound care and surgical recovery. It competes in the same complex wound and surgical reconstruction segments as PolyNova, particularly in diabetic foot ulcers and chronic wounds.
• LifeNet Health: LifeNet Health distributes AlloDerm, a leading acellular dermal matrix used in reconstruction and wound care. AlloDerm is one of the primary biologic alternatives PolyNova targets with its synthetic NovoSorb BTM and MTX platform.
• Cook Medical (Cook Biotech): Cook Biotech manufactures biologic wound care and tissue repair products including OASIS Wound Matrix, a competitor in the dermal substitute and wound healing market. It competes directly with PolyNova's MTX and BTM in hospital-based wound reconstruction applications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xtwitter.com/polynovoltd
• YouTubevimeo.com/polynovo
• Facebookfacebook.com/PolyNovo
• LinkedInlinkedin.com/company/polynovo-biomaterials-pty-ltd

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PONYNOV